title: Anti-angiogenic effects of epigallocatechin-3-gallate in human skin.
abstract: Epigallocatechin-3-gallate (EGCG) is the main polyphenol component of green tea. This compound exhibits antioxidant, immunomodulatory, photoprotective, anti-angiogenic, and anti-inflammatory properties. We conducted a small randomized, double blind, split face trial using a cream containing 2.5% w/w of EGCG. Four healthy volunteers with significant erythema and telangiectasia on the face applied EGCG cream to one side of the face, and vehicle control cream to the other, twice daily for six weeks. After six weeks, biopsies were taken from EGCG and vehicle treated sites. Immunohistochemistry was used to measure VEGF and HIF-1 α. HIF-1 α expression was decreased in EGCG treated sites, such that 28.4% of the epidermis showed positive staining in vehicle treated vs. 13.8% in EGCG treated sites (p<0.001). A similar decrease in VEGF expression was found (6.7% in EGCG vs. 11.0%in in vehicle-treated skin (p<0.005). EGCG topical treatments influence HIF-1 α induction and VEGF expression and may serve as a potential agent in the prevention of telangiectasias.
authors.affiliation: University Hospitals Case Medical Center, Department of Dermatology, Cleveland, OH 44106, USA.
authors.forename: Diana Santo
authors.initials: DS
authors.lastname: Domingo
authors.forename: Melissa M
authors.initials: MM
authors.lastname: Camouse
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Hsia
authors.forename: Mary
authors.initials: M
authors.lastname: Matsui
authors.forename: Daniel
authors.initials: D
authors.lastname: Maes
authors.forename: Nicole L
authors.initials: NL
authors.lastname: Ward
authors.forename: Kevin D
authors.initials: KD
authors.lastname: Cooper
authors.forename: Elma D
authors.initials: ED
authors.lastname: Baron
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D002392:Catechin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004304:Dosage Forms; D004311:Double-Blind Method; D004890:Erythema / Q000188:drug therapy* / Q000473:pathology; D005145:Face / Q000473:pathology*; D005260:Female; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000096:biosynthesis / Q000187:drug effects; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D012867:Skin; D013684:Telangiectasis / Q000188:drug therapy* / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D004304:Dosage Forms; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D042461:Vascular Endothelial Growth Factor A; D002392:Catechin; C045651:epigallocatechin gallate